嘉因生物 Exegenesis Bio 宣布完成 B++ 轮融资;迄今为止共筹集了 1.2 亿美元

费城办事处,2021 年 6 月 23 日讯:嘉因生物 Exegenesis Bio 是一家快速发展的全球基因治疗公司,致力于开发针对眼科、中枢神经系统和肝脏疾病的创新基因药物,在此很高兴地宣布完成其 B++ 系列融资,本轮风险投资超过 5000 万美元。本轮融资由高瓴资本领投,现有投资者LYFE Capital和BioTrack Capital,以及新投资者淡马锡控股、CPE和Lake Bleu Capital。点击这里读取完整的新闻稿

PHILADELPHIA, PA, June 23, 2021 (BUSINESS WIRE) – Exegenesis Bio, a rapidly growing global gene therapy company, developing innovative genetic medicines for eye, CNS and liver-directed diseases is pleased to announce the completion of its series B++ financing, raising over $50 M of venture investments in this round. The round was led by Hillhouse Capital Group and included existing investors LYFE Capital and BioTrack Capital, as well as new investors Temasek Holdings, CPE and Lake Bleu Capital. Read full press release

Scroll to top